Biotech · Private company
Asahi Kasei Therapeutics, Inc.
Track this companyFree. Adds Asahi Kasei Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials257 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- LCP-AtorFenPhase 3 · DyslipidemiaClinicalTrials.gov · fetched Nov 12, 2026
- atorvastatinPhase 2 · DyslipidemiaClinicalTrials.gov · fetched Nov 12, 2026
- AzathioprinePhase 2 · Autoimmune HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- fenofibratePhase 2 · DyslipidemiaClinicalTrials.gov · fetched Nov 12, 2026
- LCP-Tacro (tacrolimus)Phase 2 · Autoimmune HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Tacrolimus (TAC)Phase 2 · Transplantation, KidneyClinicalTrials.gov · fetched Nov 12, 2026
- VEL-101Phase 2 · Transplantation, KidneyClinicalTrials.gov · fetched Nov 12, 2026
- thrombomodulin alfaPhase 1 · Chemotherapy-induced Peripheral NeuropathyClinicalTrials.gov · fetched Nov 12, 2026
- VEL-101Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- VEL-101 to Prevent Rejection After Kidney TransplantationPHASE2 · RECRUITING · started Aug 18, 2026ClinicalTrials.gov NCT07290777 · fetched Nov 12, 2026
- Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant RecipientsPHASE4 · RECRUITING · started Mar 17, 2026ClinicalTrials.gov NCT06751992 · fetched Nov 12, 2026
- Early Use of Long-acting Tacrolimus in Lung Transplant RecipientsEARLY_PHASE1 · RECRUITING · started Dec 1, 2023ClinicalTrials.gov NCT04469842 · fetched Nov 12, 2026
- A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101PHASE1 · COMPLETED · started Apr 26, 2022ClinicalTrials.gov NCT05238493 · fetched Nov 12, 2026
- Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer PatientsPHASE1 · TERMINATED · started Mar 24, 2022ClinicalTrials.gov NCT05251727 · fetched Nov 12, 2026
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXRPHASE4 · TERMINATED · started Nov 23, 2021ClinicalTrials.gov NCT04773392 · fetched Nov 12, 2026
- Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR TacrolimusPHASE4 · UNKNOWN · started Aug 16, 2021ClinicalTrials.gov NCT04917718 · fetched Nov 12, 2026
- Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™PHASE4 · COMPLETED · started Jun 22, 2021ClinicalTrials.gov NCT04838288 · fetched Nov 12, 2026
- Envarsus Neurotoxicity Burden in Liver Transplant PatientsPHASE4 · COMPLETED · started Jan 31, 2020ClinicalTrials.gov NCT03823768 · fetched Nov 12, 2026
- Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release TacrolimusPHASE4 · COMPLETED · started Jan 16, 2020ClinicalTrials.gov NCT03760263 · fetched Nov 12, 2026
- Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant RecipientsPHASE4 · COMPLETED · started Jan 9, 2020ClinicalTrials.gov NCT04225988 · fetched Nov 12, 2026
- Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney TransplantsPHASE4 · ACTIVE_NOT_RECRUITING · started Nov 11, 2019ClinicalTrials.gov NCT03841097 · fetched Nov 12, 2026
- Envarsus XR Compared to Immediate Release TacrolimusPHASE4 · COMPLETED · started Jul 18, 2019ClinicalTrials.gov NCT03979365 · fetched Nov 12, 2026
- Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic ProfilePHASE2_PHASE3 · RECRUITING · started Mar 28, 2019ClinicalTrials.gov NCT03321656 · fetched Nov 12, 2026
- Envarsus in Delayed Graft Function (E-DGF)PHASE4 · COMPLETED · started Mar 18, 2019ClinicalTrials.gov NCT03864926 · fetched Nov 12, 2026
- CIRTEN-Simultaneous Pancreas-Kidney Transplant RecipientsPHASE2_PHASE3 · RECRUITING · started Feb 27, 2019ClinicalTrials.gov NCT03769298 · fetched Nov 12, 2026
- Envarsus XR® in Adolescent Renal Transplant RecipientsPHASE4 · ACTIVE_NOT_RECRUITING · started Jan 15, 2019ClinicalTrials.gov NCT03266393 · fetched Nov 12, 2026
- Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant RecipientsPHASE4 · COMPLETED · started Nov 12, 2018ClinicalTrials.gov NCT03713645 · fetched Nov 12, 2026
- Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.EARLY_PHASE1 · COMPLETED · started Oct 24, 2018ClinicalTrials.gov NCT03410654 · fetched Nov 12, 2026
- Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney TransplantationPHASE4 · COMPLETED · started Jul 26, 2018ClinicalTrials.gov NCT03511560 · fetched Nov 12, 2026
- Once Daily Immunosuppression RegimenPHASE4 · TERMINATED · started Jun 4, 2018ClinicalTrials.gov NCT03555448 · fetched Nov 12, 2026
- Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant RecipientsPHASE4 · COMPLETED · started Apr 1, 2018ClinicalTrials.gov NCT03461445 · fetched Nov 12, 2026
- LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune HepatitisPHASE2 · TERMINATED · started Dec 1, 2007ClinicalTrials.gov NCT00608894 · fetched Nov 12, 2026
- 12-Month, Open-Label, Extension Study of LCP-AtorFen in DyslipidemiaPHASE2_PHASE3 · COMPLETED · started Oct 1, 2007ClinicalTrials.gov NCT00664859 · fetched Nov 12, 2026
- Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in DyslipidemiaPHASE2 · COMPLETED · started Jul 1, 2007ClinicalTrials.gov NCT00504829 · fetched Nov 12, 2026